Clinical trials: Immunosuppression Management
Liver Disease
Randomized Controlled Trial of ImmuKnow in Liver Transplantation
ImmuKnow detects cell-mediated immunity in solid-organ transplant recipients undergoing immunosuppressive therapy. Increasing ImmuKnow values indicate a decrease of immunosuppression and decreasing ImmuKnow values suggest an…
- Trial name
- NCT01764581
- Testing
- Tacrolimus regulation according to ImmuKnow values
- Volunteers
- 206 people
- Sponsor
- University of Bologna
Kidney Transplantation
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection.
- Trial name
- NCT00483756
- Testing
- Cyclosporine, CP-690,550
- Where
- 69 sites in United States, Australia and 13 more
- Volunteers
- 338 people
- Sponsor
- Pfizer
Pharmacokinetics, Drug Interactions
Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects
The purpose of this study is to confirm a significant influence of ezetimibe and tacrolimus on each others pharmacokinetics
- Conditions
- Pharmacokinetics, Drug Interactions, Hypercholesterolemia, Immunosuppression
- Trial name
- NCT00621699
- Testing
- 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany, 1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany, 1 tablet Ezetrol(R) + 1 capsules Prograf(R)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Immunosuppression
Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients
With the availability of well-studied once-daily formulations of tacrolimus, the ability to achieve a true once-daily immunosuppressant regimen along with everolimus and steroids may finally be achievable and have the potential…
- Trial name
- NCT02954198
- Testing
- Tacrolimus, Prednisone, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical University of South Carolina
Pharmacokinetics, Drug Interactions
Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects
The purpose of this study is to confirm a significant influence of ezetimibe and sirolimus on each others pharmacokinetics
- Conditions
- Pharmacokinetics, Drug Interactions, Hypercholesterolemia, Immunosuppression
- Trial name
- NCT00621101
- Testing
- 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany, 1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany, 1 tablet Ezetrol(R) + 1 tablet Rapamune(R)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Kidney Transplant Rejection, Immunosuppression
Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test
This is an investigator-initiated, single-center, prospective, randomized, proof of concept study. In this study patients who are status post kidney transplantation and meet the inclusion and exclusion criteria will undergo…
- Trial name
- NCT04670926
- Testing
- TruGraf, Standard of Care
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Transplant Genomics, Inc.
End-stage Renal Disease
Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
This 2 x 2 sequential factorial study evaluates two potential improvements to the standard immunosuppression regimen used at the investigators' institution to prevent rejection of transplanted kidneys.
- Trial name
- NCT00556933
- Testing
- rabbit anti-thymocyte globulin - single dose, mycophenolate mofetil, rabbit anti-thymocyte globulin - 4 doses
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Nebraska
Rejection Heart Transplant, Immunosuppression
Improving Immunosuppressive Therapy in Heart Transplantation
Cardiac allograft rejection (CAR) occurs in 30% to 40% of transplant recipients within the first year post-transplant, and carries an increased risk of both acute graft failure and reduced graft longevity.
- Trial name
- NCT03932539
- Where
- 4 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Uveitis
A Clinical Trial of Infliximab for Uveitis
This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha (TNF-alpha) and its receptors using Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed…
- Trial name
- NCT00273390
- Testing
- Remicade (infliximab)
- Volunteers
- 32 people
- Sponsor
- Oregon Health and Science University